Topical Ocular Biologics with Claris Bio's Clarke Atwell

Business Of Biotech

We love to hear from our listeners. Send us a message.

Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil Chauhan, ClarisBio is rewriting the ophthalmology rulebook. CEO Clark Atwell acknowledges that it's not the first to bring topically-administered biologic therapies to the front of the eye, but if successful in the clinic, its Neurotrophic Keratitis candidate will vastly improve the patient experience. It will also prove unequivocally that there's biotech business value in front-of-the-eye therapeutics, as opposed to just parenterally-administered back-of-the-eye biologics. On this episode of the Business of Biotech podcast, Atwell shares the stories of his career focus on the cornea, Claris' founding and funding progress, and why there's big, multi-indication opportunity for the company's novel HGF therapeutics in corneal diseases.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Chapter

1. Innovating Ophthalmology (00:00:00)

2. Impact of Specializing in Ophthalmology (00:07:30)

3. Deciding Disease Applications for Lead Molecule (00:13:21)

4. Navigating Funding Landscape (00:22:12)

5. Revolutionizing Ophthalmology Drug Delivery (00:37:27)

6. Advancing Clinical Trials at CLARIS (00:51:10)